330 related articles for article (PubMed ID: 18363493)
1. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.
Tassinari D; Sartori S; Tamburini E; Scarpi E; Raffaeli W; Tombesi P; Maltoni M
J Palliat Med; 2008 Apr; 11(3):492-501. PubMed ID: 18363493
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Wolff RF; Aune D; Truyers C; Hernandez AV; Misso K; Riemsma R; Kleijnen J
Curr Med Res Opin; 2012 May; 28(5):833-45. PubMed ID: 22443154
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis.
Yang Q; Xie DR; Jiang ZM; Ma W; Zhang YD; Bi ZF; Chen DL
J Exp Clin Cancer Res; 2010 Jun; 29(1):67. PubMed ID: 20529380
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
5. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
7. [Transdermal opiates in the treatment of moderate-severe cancer pain. Recommendations for clinical practice].
Tassinari D; Drudi F; Carloni F; Castellani C; Scarpi E; Maltoni M
Recenti Prog Med; 2009 Dec; 100(12):551-8. PubMed ID: 20178309
[TBL] [Abstract][Full Text] [Related]
8. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
Muijsers RB; Wagstaff AJ
Drugs; 2001; 61(15):2289-307. PubMed ID: 11772140
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
10. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
[TBL] [Abstract][Full Text] [Related]
11. Transdermal fentanyl for cancer pain.
Hadley G; Derry S; Moore RA; Wiffen PJ
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010270. PubMed ID: 24096644
[TBL] [Abstract][Full Text] [Related]
12. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials.
Tassinari D; Sartori S; Tamburini E; Scarpi E; Tombesi P; Santelmo C; Maltoni M
J Palliat Care; 2009; 25(3):172-80. PubMed ID: 19824278
[TBL] [Abstract][Full Text] [Related]
13. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
15. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R
J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine for treating cancer pain.
Schmidt-Hansen M; Bromham N; Taubert M; Arnold S; Hilgart JS
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009596. PubMed ID: 25826743
[TBL] [Abstract][Full Text] [Related]
17. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Radbruch L; Sabatowski R; Loick G; Kulbe C; Kasper M; Grond S; Lehmann KA
Palliat Med; 2000 Mar; 14(2):111-9. PubMed ID: 10829145
[TBL] [Abstract][Full Text] [Related]
18. A comparison of opioid-related adverse events with fentanyl iontophoretic transdermal system versus morphine intravenous patient-controlled analgesia in acute postoperative pain.
Viscusi ER; Grond S; Ding L; Danesi H; Jones JB; Sinatra RS
Pain Manag; 2016; 6(1):19-24. PubMed ID: 26376128
[TBL] [Abstract][Full Text] [Related]
19. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain.
Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H
Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339
[TBL] [Abstract][Full Text] [Related]
20. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
Donner B; Zenz M; Tryba M; Strumpf M
Pain; 1996 Mar; 64(3):527-534. PubMed ID: 8783318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
